Emgality (galcanezumab-gnlm subcutaneous injection – Lilly) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has ≥ 4 migraine headache days per month (prior to initiating a migraine-preventive medication)
• If the patient is currently taking Emgality, the patient has had a significant clinical benefit from the medication as determined by the prescriber

Approval duration

1 year